Evidence map›Paper›PMID 29038466›Full record

ArticleNature communications2017

Replication fork reversal triggers fork degradation in BRCA2-defective cells.

Sofija Mijic, Ralph Zellweger, Nagaraja Chappidi, Matteo Berti, Kurt Jacobs, Karun Mutreja, Sebastian Ursich, Arnab Ray Chaudhuri, Andre Nussenzweig, Pavel Janscak and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 252 papers.

0numbers the graph read from it
0cells of the map it votes in
252citing papers in PubMed
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

252 citing papers in PubMed, 368 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. PARP1-mediated 5' flap dynamics facilitate Okazaki fragment maturation.bioRxiv : the preprint server for biology · 2026
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

192 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Sofija MijicInstitute of Molecular Cancer Research, University of Zurich, 8057, Zurich, Switzerland.
Ralph ZellwegerInstitute of Molecular Cancer Research, University of Zurich, 8057, Zurich, Switzerland.
Nagaraja ChappidiInstitute of Molecular Cancer Research, University of Zurich, 8057, Zurich, Switzerland.
Matteo BertiInstitute of Molecular Cancer Research, University of Zurich, 8057, Zurich, Switzerland.
Kurt JacobsInstitute of Molecular Cancer Research, University of Zurich, 8057, Zurich, Switzerland.
Karun MutrejaInstitute of Molecular Cancer Research, University of Zurich, 8057, Zurich, Switzerland.
Sebastian UrsichInstitute of Molecular Cancer Research, University of Zurich, 8057, Zurich, Switzerland.
Arnab Ray ChaudhuriLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA.
Andre NussenzweigLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA.
Pavel JanscakInstitute of Molecular Cancer Research, University of Zurich, 8057, Zurich, Switzerland.
Massimo LopesInstitute of Molecular Cancer Research, University of Zurich, 8057, Zurich, Switzerland. lopes@imcr.uzh.ch.
University of Zurich · CHNational Cancer Institute · US

Funding

Relationship between DNA damage detection and signalingZIABC010959 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NUSSENZWEIG, ANDRE A. · 2009 to 2025
$27.0M
European Research Council 617102
6 · The paper itself

Abstract

Besides its role in homologous recombination, the tumor suppressor BRCA2 protects stalled replication forks from nucleolytic degradation. Defective fork stability contributes to chemotherapeutic sensitivity of BRCA2-defective tumors by yet-elusive mechanisms. Using DNA fiber spreading and direct visualization of replication intermediates, we report that reversed replication forks are entry points for fork degradation in BRCA2-defective cells. Besides MRE11 and PTIP, we show that RAD52 promotes stalled fork degradation and chromosomal breakage in BRCA2-defective cells. Inactivation of these factors restores reversed fork frequency and chromosome integrity in BRCA2-defective cells. Conversely, impairing fork reversal prevents fork degradation, but increases chromosomal breakage, uncoupling fork protection, and chromosome stability. We propose that BRCA2 is dispensable for RAD51-mediated fork reversal, but assembles stable RAD51 nucleofilaments on regressed arms, to protect them from degradation. Our data uncover the physiopathological relevance of fork reversal and illuminate a complex interplay of homologous recombination factors in fork remodeling and stability.BRCA2 is involved in both homologous recombination (HR) and the protection of stalled replication forks from degradation. Here the authors reveal how HR factors cooperate in fork remodeling, showing that BRCA2 supports RAD51 loading on the regressed arms of reversed replication forks to protect them from degradation.

Indexed as

DNA ReplicationHomologous RecombinationBRCA2 ProteinCarrier ProteinsCell Line, TumorChromosomal InstabilityDNA-Binding ProteinsHumansMRE11 Homologue ProteinNuclear ProteinsRad51 RecombinaseRad52 DNA Repair and Recombination ProteinBRCA2 ProteinBRCA2 protein, humanCarrier ProteinsDNA-Binding ProteinsMRE11 Homologue ProteinMRE11 protein, humanNuclear ProteinsPAXIP1 protein, humanRAD51 protein, humanRad51 RecombinaseRad52 DNA Repair and Recombination ProteinRAD52 protein, human

Identifiers

PMID29038466
PMCPMC5643541
OpenAlexW2763248055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.